Influenza Vaccine Enhancement with Immunomodulating Peptide Thymosin Alpha 1 - Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination. - BioPharm

ADVERTISEMENT

Influenza Vaccine Enhancement with Immunomodulating Peptide Thymosin Alpha 1
Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination.


BioPharm International Supplements


35. Yao Q, Doan LX, Zhang R, Bharadwaj U, Li M, Chen C. Thymosin-alpha1 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes. Immunol Lett. 2007;110(2):110–20.

36. Yao W, Zhu Q, Yuan Y, Qiao M, Zhang Y, Zhai Z. Thymosin alpha 1 improves severe acute pancreatitis in rats via regulation of peripheral T cell number and cytokine serum level. J Gastroenterol Hepatol. 2007;22(11):1866–71.

37. Iijima N, Yanagawa Y, Onoe K. Role of early- or late-phase activation of p38 mitogen-activated protein kinase induced by tumour necrosis factor-alpha or 2,4-dinitrochlorobenzene during maturation of murine dendritic cells. Immunol 2003;110(3):322–8.

38. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol. 2001;166(6):3837–45.

39. Goldstein A, Goldstein A. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opinion Biological Therapy 2009;9:593-6-8.

40. Tuthill C. Issues in pharmaceutical development of thymosin alpha 1 from preclinical studies through marketing. Annals New York Acad Sci. 2007;1112:351–56.

41. Ershler W, Moore A, Hacker M, Ninomiya J, Naylor P, Goldstein A. Specific antibody synthesis in vitro. II. Age-associated thymosin enhancement of antitetanus antibody synthesis. Immunopharmacology. 1984;8:69–77.

42. Crosnier J, Jungers P, Courouc AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet 1981;1(8218):455–9.

43. Grob P, Binswanger U, Zaruba K, Joller-Jemelka H, Schmid M, Hacki W, et al. Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Research 1983;3:43–52.

44. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984;311(8):496–501.

45. Gravenstein S, Ershler WB, Drumaskin S, Schwab R, Weksler ME. Anti-influenza antibody response: augmentation in elderly "non-responders" by thymosin alpha 1. Gerontologist. 1986;26:150A.

46. Gravenstein S, Duthie EH, Miller BA, Roecker E, Drinka P, Prathipati K, et al. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J Ame Geriatric Soc. 1989;37:1–8.

47. McConnell L, Gravenstein S, Roecker E, Spencer S, Simon G, Ershler W. Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin alpha 1. Gerontologist. 1989;29:188A.

48. Shen SY, Corteza QB, Josselson J, Gravenstein S, Ershler WB, Sadler JH, et al. Age-dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients. In: Goldstein AL, editor. Biomedical Advances in Aging. New York: Plenum Press; 1990. pp. 523–30.

49. Shen S, Josselson J, McRoy C, Sadler J, Chretien P. Effect of thymosin alpha 1 on Heptavax-B vaccination among hemodialysis patients. Kidney Int. 1987:31:217.

50. Shen S, Josselson J, McRoy C, Sadler J, Chretien P. Effects of thymosin alpha 1 on peripheral T-cell and Heptavax-B vaccination in previously non-responsive hemodialysis patients. Hepatol. 1987;7(5):1120.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here